NCT04487210View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 7, 2020

Primary Completion Date

June 1, 2021

Study Completion Date

December 6, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

MVC-COV1901

MVC-COV1901 is formulated in the different dosages of Spike (S) protein with CpG 1018 and aluminum content as adjuvant.

Trial Locations (1)

Unknown

National Taiwan University Hospital, Taipei

Sponsors
All Listed Sponsors
lead

Medigen Vaccine Biologics Corp.

INDUSTRY

NCT04487210 - A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19 | Biotech Hunter | Biotech Hunter